2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Melanoma
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Secondary Malignant Neoplasm of Bone
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Desmoid Tumors
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
10
Cisplatin
9
Cetuximab
9
Paclitaxel
5
Radiotherapy
4
Nivolumab
4
Fluorouracil
4
zalutumumab
3
Docetaxel
3
Taxes
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Gefitinib
2
Cyclophosphamide
2
Carboplatin
2
temsirolimus
1
sintilimab
1
poly ICLC
1
osimertinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
cobimetinib
1
atezolizumab
1
advexin
1
abemaciclib
1
Vorinostat
1
Sorafenib
1
Risk Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled